|
Market Closed -
Other stock markets
|
After hours 17:20:43 | |||
| 117.50 EUR | -0.04% |
|
117.60 | +0.09% |
| 04-16 | Merck KGaA Price Target, Forecasts Cut as AlphaValue/Baader Europe Notes 'Restrained' Growth Prospects | MT |
| 04-16 | Merck: Pharma business’s reinvigoration remains key for re-rating | ![]() |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.24 | 6.68 | 4.76 | 5.26 | 4.76 | |||||
Return on Total Capital | 8.87 | 9.13 | 6.32 | 6.84 | 6.07 | |||||
Return On Equity % | 15.95 | 14.09 | 10.74 | 9.82 | 8.92 | |||||
Return on Common Equity | 15.96 | 14.07 | 10.74 | 9.81 | 8.92 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 62.79 | 61.79 | 59.23 | 59.21 | 58.9 | |||||
SG&A Margin | 27.8 | 26.59 | 27.55 | 27.39 | 28.18 | |||||
EBITDA Margin % | 29.61 | 29.5 | 24.89 | 27.94 | 27.01 | |||||
EBITA Margin % | 26.19 | 26.29 | 21.33 | 23.29 | 22.27 | |||||
EBIT Margin % | 22.11 | 22.55 | 17.6 | 19.92 | 18.62 | |||||
Income From Continuing Operations Margin % | 15.57 | 15.02 | 13.5 | 13.17 | 12.39 | |||||
Net Income Margin % | 15.52 | 14.96 | 13.45 | 13.13 | 12.36 | |||||
Net Avail. For Common Margin % | 15.52 | 14.96 | 13.45 | 13.13 | 12.36 | |||||
Normalized Net Income Margin | 13.06 | 13.37 | 10.92 | 12.36 | 11.51 | |||||
Levered Free Cash Flow Margin | 14.55 | 10.29 | 8.94 | 8.22 | 12.46 | |||||
Unlevered Free Cash Flow Margin | 15.32 | 10.84 | 9.71 | 8.9 | 13.43 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.45 | 0.47 | 0.43 | 0.42 | 0.41 | |||||
Fixed Assets Turnover | 2.89 | 2.88 | 2.43 | 2.22 | 2.11 | |||||
Receivables Turnover (Average Receivables) | 5.67 | 5.66 | 5.18 | 5.34 | 5.39 | |||||
Inventory Turnover (Average Inventory) | 2.04 | 1.99 | 1.85 | 1.89 | 1.92 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.05 | 1.28 | 1.42 | 1.19 | 1.46 | |||||
Quick Ratio | 0.65 | 0.75 | 0.84 | 0.71 | 0.9 | |||||
Operating Cash Flow to Current Liabilities | 0.44 | 0.45 | 0.43 | 0.41 | 0.43 | |||||
Days Sales Outstanding (Average Receivables) | 64.38 | 64.51 | 70.5 | 68.59 | 67.77 | |||||
Days Outstanding Inventory (Average Inventory) | 179.24 | 183.29 | 197.66 | 193.41 | 190.35 | |||||
Average Days Payable Outstanding | 60.68 | 62.05 | 71.74 | 70.64 | 60.98 | |||||
Cash Conversion Cycle (Average Days) | 182.94 | 185.75 | 196.43 | 191.37 | 197.14 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 50.43 | 40.1 | 37.16 | 34.35 | 41.76 | |||||
Total Debt / Total Capital | 33.53 | 28.62 | 27.09 | 25.57 | 29.46 | |||||
LT Debt/Equity | 38.62 | 35.38 | 34.53 | 23.33 | 37.44 | |||||
Long-Term Debt / Total Capital | 25.67 | 25.25 | 25.18 | 17.37 | 26.41 | |||||
Total Liabilities / Total Assets | 52.79 | 46.41 | 44.83 | 41.85 | 44.38 | |||||
EBIT / Interest Expense | 17.84 | 25.58 | 14.21 | 18.4 | 12.06 | |||||
EBITDA / Interest Expense | 24.47 | 34.23 | 20.67 | 25.81 | 17.48 | |||||
(EBITDA - Capex) / Interest Expense | 20.1 | 26.42 | 13.72 | 18.38 | 12.62 | |||||
Total Debt / EBITDA | 1.81 | 1.55 | 1.85 | 1.74 | 2.1 | |||||
Net Debt / EBITDA | 1.47 | 1.24 | 1.4 | 1.22 | 1.51 | |||||
Total Debt / (EBITDA - Capex) | 2.2 | 2.01 | 2.79 | 2.45 | 2.91 | |||||
Net Debt / (EBITDA - Capex) | 1.79 | 1.61 | 2.11 | 1.72 | 2.1 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 12.28 | 12.93 | -5.57 | 0.78 | -0.26 | |||||
Gross Profit, 1 Yr. Growth % | 14.97 | 11.12 | -9.45 | 0.72 | -0.77 | |||||
EBITDA, 1 Yr. Growth % | 26.99 | 13.3 | -19.87 | 7.18 | -3.49 | |||||
EBITA, 1 Yr. Growth % | 31.23 | 14.39 | -22.9 | 6.69 | -4.55 | |||||
EBIT, 1 Yr. Growth % | 41.75 | 16.44 | -25.77 | 9.85 | -6.65 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 53.71 | 8.97 | -15.15 | -1.69 | -6.14 | |||||
Net Income, 1 Yr. Growth % | 53.75 | 8.87 | -15.09 | -1.66 | -6.09 | |||||
Normalized Net Income, 1 Yr. Growth % | 51.61 | 16.79 | -22.27 | 9.86 | -7.12 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 53.75 | 8.87 | -15.16 | -1.58 | -6.09 | |||||
Accounts Receivable, 1 Yr. Growth % | 15.62 | 11.01 | -3.82 | -0.55 | -1.82 | |||||
Inventory, 1 Yr. Growth % | 18.4 | 18.77 | 0.11 | -3.3 | 1.74 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 12.4 | 13.66 | 10.39 | 10.7 | -0.85 | |||||
Total Assets, 1 Yr. Growth % | 8.53 | 6.98 | -0.08 | 6.33 | -0.13 | |||||
Tangible Book Value, 1 Yr. Growth % | -50.83 | -106.41 | 1.03K | 96.15 | -32.75 | |||||
Common Equity, 1 Yr. Growth % | 25.92 | 21.51 | 2.9 | 12.11 | -4.42 | |||||
Cash From Operations, 1 Yr. Growth % | 32.76 | -7.73 | -11.15 | 21.19 | -14.26 | |||||
Capital Expenditures, 1 Yr. Growth % | -24.56 | 43.62 | 18.03 | -5.81 | -6.87 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 53.79 | -19.44 | -17.16 | -11.47 | 51.2 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 45.92 | -19.47 | -14.61 | -11.5 | 50.52 | |||||
Dividend Per Share, 1 Yr. Growth % | 32.14 | 18.92 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 10.4 | 12.6 | 3.26 | -2.45 | 0.26 | |||||
Gross Profit, 2 Yr. CAGR % | 10.08 | 13.03 | 0.29 | -4.49 | -0.03 | |||||
EBITDA, 2 Yr. CAGR % | 17.34 | 19.52 | -4.98 | -4.81 | 1.67 | |||||
EBITA, 2 Yr. CAGR % | 18.48 | 21.96 | -6.38 | -7.89 | 0.87 | |||||
EBIT, 2 Yr. CAGR % | 30.58 | 27.78 | -7.37 | -7.99 | 1.22 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 53.84 | 29.42 | -3.84 | -8.67 | -3.94 | |||||
Net Income, 2 Yr. CAGR % | 52.13 | 29.38 | -3.86 | -8.63 | -3.9 | |||||
Normalized Net Income, 2 Yr. CAGR % | 39.15 | 32.39 | -5.08 | -5.83 | 1.02 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 53.81 | 29.38 | -3.89 | -8.63 | -3.86 | |||||
Accounts Receivable, 2 Yr. CAGR % | 6.13 | 13.29 | 3.33 | -2.2 | -1.19 | |||||
Inventory, 2 Yr. CAGR % | 8.03 | 18.58 | 9.04 | -1.61 | -0.81 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 7.96 | 13.03 | 12.02 | 10.54 | 4.77 | |||||
Total Assets, 2 Yr. CAGR % | 1.76 | 7.75 | 3.4 | 3.08 | 3.08 | |||||
Tangible Book Value, 2 Yr. CAGR % | -37.88 | -82.25 | -16.53 | 369.78 | 14.57 | |||||
Common Equity, 2 Yr. CAGR % | 9.36 | 23.69 | 11.82 | 7.41 | 3.52 | |||||
Cash From Operations, 2 Yr. CAGR % | 27.13 | 10.68 | -9.46 | 3.77 | 1.94 | |||||
Capital Expenditures, 2 Yr. CAGR % | 14.51 | 4.09 | 30.2 | 5.44 | -6.34 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 16.9 | 10.82 | -18.69 | -12.38 | 15.68 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 13.36 | 7.96 | -17.44 | -11.21 | 15.4 | |||||
Dividend Per Share, 2 Yr. CAGR % | 19.29 | 25.36 | 9.05 | 0 | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 9.89 | 11.24 | 6.19 | 2.43 | -1.72 | |||||
Gross Profit, 3 Yr. CAGR % | 9.2 | 10.43 | 4.97 | 0.44 | -3.27 | |||||
EBITDA, 3 Yr. CAGR % | 16.63 | 15.7 | 4.41 | 0.7 | -4.39 | |||||
EBITA, 3 Yr. CAGR % | 17.83 | 16.74 | 4.46 | -1.2 | -6.81 | |||||
EBIT, 3 Yr. CAGR % | 30.07 | 25.23 | 6.36 | -0.72 | -7.58 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 41.02 | 37.14 | 12.43 | -3.13 | -7.83 | |||||
Net Income, 3 Yr. CAGR % | -3.26 | 36.08 | 12.43 | -3.13 | -7.79 | |||||
Normalized Net Income, 3 Yr. CAGR % | 34.62 | 30.81 | 10.58 | 0.92 | -6.26 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 41.82 | 37.08 | 12.4 | -3.13 | -7.79 | |||||
Accounts Receivable, 3 Yr. CAGR % | 7.93 | 7.73 | 7.27 | 2.02 | -2.07 | |||||
Inventory, 3 Yr. CAGR % | 12.16 | 11.49 | 12.07 | 4.76 | -0.51 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 14.47 | 9.83 | 12.14 | 11.58 | 6.61 | |||||
Total Assets, 3 Yr. CAGR % | 7.14 | 3.47 | 5.08 | 4.37 | 2.01 | |||||
Tangible Book Value, 3 Yr. CAGR % | -4.81 | -70.87 | -30.02 | 10.97 | 145.35 | |||||
Common Equity, 3 Yr. CAGR % | 7.45 | 13.27 | 16.33 | 11.92 | 3.32 | |||||
Cash From Operations, 3 Yr. CAGR % | 27.65 | 14.25 | 2.86 | -0.22 | -2.63 | |||||
Capital Expenditures, 3 Yr. CAGR % | 5.42 | 23.49 | 8.54 | 16.88 | 1.16 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 10.29 | 2.96 | 0.26 | -15.06 | 5.09 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 9.43 | 0.87 | -0.45 | -14.31 | 5.86 | |||||
Dividend Per Share, 3 Yr. CAGR % | 13.96 | 19.17 | 16.26 | 5.95 | 0 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 5.56 | 8.9 | 7.19 | 5.55 | 3.77 | |||||
Gross Profit, 5 Yr. CAGR % | 4.71 | 7.7 | 5.55 | 4.19 | 2.94 | |||||
EBITDA, 5 Yr. CAGR % | 6.76 | 8.35 | 7.3 | 6.9 | 4.42 | |||||
EBITA, 5 Yr. CAGR % | 7.01 | 8.64 | 7.28 | 6.05 | 3.65 | |||||
EBIT, 5 Yr. CAGR % | 12.12 | 13.52 | 13.31 | 10.54 | 5.06 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 13.42 | 5.48 | 20.99 | 16.56 | 5.57 | |||||
Net Income, 5 Yr. CAGR % | 13.4 | 5.01 | -3.5 | 16.04 | 5.59 | |||||
Normalized Net Income, 5 Yr. CAGR % | 14.2 | 14.66 | 16.82 | 14.52 | 7.46 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 13.38 | 5.48 | 21.38 | 16.55 | 5.59 | |||||
Accounts Receivable, 5 Yr. CAGR % | 5.21 | 7.18 | 6.06 | 3.64 | 3.8 | |||||
Inventory, 5 Yr. CAGR % | 8.37 | 11.97 | 10.9 | 6.06 | 6.73 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 11.27 | 12.7 | 13.49 | 10.12 | 9.13 | |||||
Total Assets, 5 Yr. CAGR % | 3.47 | 6.38 | 5.62 | 3.32 | 4.28 | |||||
Tangible Book Value, 5 Yr. CAGR % | -21.51 | -51.59 | -9.69 | -12.01 | -14.77 | |||||
Common Equity, 5 Yr. CAGR % | 8.81 | 13.11 | 9.18 | 10.89 | 11.03 | |||||
Cash From Operations, 5 Yr. CAGR % | 12.89 | 9.58 | 11.26 | 9.93 | 2.49 | |||||
Capital Expenditures, 5 Yr. CAGR % | 8.29 | 10.75 | 14.71 | 15.92 | 2.32 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 4.36 | -0.47 | -2.54 | -3.66 | 7.14 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 3.87 | -0.94 | -2.4 | -4.32 | 6.51 | |||||
Dividend Per Share, 5 Yr. CAGR % | 9.04 | 11.97 | 11.97 | 11.1 | 9.46 |
- Stock Market
- Equities
- MRK Stock
- Financials Merck KGaA
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
















